Immix Biopharma Completes Enrollment for Key Phase 2 Trial
Immix Biopharma (NASDAQ:IMMX) has completed enrollment in its NEXICART-2 Phase 2 clinical trial, a critical step toward regulatory approval of its CAR-T cell therapy NXC-201. The company expects to release top-line results by Q3 2026 and plans for a BLA submission followed by commercial launch.
Tickers: $IMMX
Topics: al amyloidosis car-t cell therapy fda approval process immunotherapy